Cell block samples from malignant pleural effusion might be valid alternative samples for anaplastic lymphoma kinase detection in patients with advanced non‐small‐cell lung cancer

To evaluate the clinical value of cell block samples from malignant pleural effusion (MPE) as alternative samples to tumour tissue for anaplastic lymphoma kinase (ALK) detection in patients with advanced non‐small‐cell lung cancer (NSCLC).

[1]  M. Tsao,et al.  Epidermal growth factor receptor mutation‐specific immunohistochemical antibodies in lung adenocarcinoma , 2014, Histopathology.

[2]  A. Majid,et al.  Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer. , 2014, Lung cancer.

[3]  Kyung-Hee Lee,et al.  Prognostic impact of minimal pleural effusion in non-small-cell lung cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  N. Lu,et al.  Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  M. Forni,et al.  The cell block technique revisited for cells cultured in adherence and as “spheres” , 2013, Histochemistry and Cell Biology.

[6]  Funda Demirağ,et al.  The Cell Block Method Increases the Diagnostic Yield in Exudative Pleural Effusions Accompanying Lung Cancer / Hücre Bloğu Yöntemi Akciğer Kanserine Eşlik Eden Eksudatif Plevral Sıvılarda Tanıyı Artırmaktadır , 2013, Turk patoloji dergisi.

[7]  R. Herbst,et al.  Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma , 2013, Cancer cytopathology.

[8]  L. Bubendorf,et al.  Detection of ALK-Positive Non–Small-Cell Lung Cancers on Cytological Specimens: High Accuracy of Immunocytochemistry with the 5A4 Clone , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[9]  R. McCormack,et al.  The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: comparison of methodologies , 2013, Journal of Clinical Pathology.

[10]  M. Hidalgo,et al.  The ALK translocation in advanced non‐small‐cell lung carcinomas: preapproval testing experience at a single cancer centre , 2013, Histopathology.

[11]  S. Bloor,et al.  Targeted Resequencing Reveals ALK Fusions in Non-Small Cell Lung Carcinomas Detected by FISH, Immunohistochemistry, and Real-Time RT-PCR: A Comparison of Four Methods , 2013, BioMed research international.

[12]  C. Couture,et al.  Immunohistochemistry is a Reliable Screening Tool for Identification of ALK Rearrangement in Non–Small-Cell Lung Carcinoma and is Antibody Dependent , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[13]  F. Hirsch,et al.  A dramatic response to crizotinib in a non-small-cell lung cancer patient with IHC-positive and FISH-negative ALK. , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[14]  A. Iafrate,et al.  Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology. , 2012, The oncologist.

[15]  J. Subramanian,et al.  Prognostic Impact of Malignant Pleural Effusion at Presentation in Patients with Metastatic Non–Small-Cell Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[16]  P. Stephens,et al.  Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer. , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[17]  Jeffrey W. Clark,et al.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. , 2010, The New England journal of medicine.

[18]  Yi Zhao,et al.  Detection and comparison of epidermal growth factor receptor mutations in cells and fluid of malignant pleural effusion in non-small cell lung cancer. , 2008, Lung cancer.